drugset / Trial / NCT03681093
Study of Efficacy of Fevipiprant in Patients With Nasal Polyposis and Asthma
RandomizedParallel-groupDouble-blindTreatment
Summary
A Phase 3b Proof-of-Concept study to evaluate the ability of fevipiprant 150 mg and 450 mg, compared with placebo, as add-on to nasal spray standard-of-care (SoC), in reducing endoscopic nasal polyp score in adult (≥ 18 years) patients with nasal polyposis and concomitant asthma.
Timeline
- Start
- 2019-03-26
- Primary completion
- 2020-05-29
- Completion
- 2020-06-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | fevipiprant | Small molecule | 150 mg | Oral |
| Subject | fevipiprant | Small molecule | 450 mg | Oral |